Yang Yu-Xin, Li Chun-Ying, Yin Wen-Jie, Chen Xia
Gastroenterology Ward III, Cangzhou Central Hospital, Cangzhou, Hebei Province, China.
J Oncol. 2022 Aug 27;2022:8762647. doi: 10.1155/2022/8762647. eCollection 2022.
To observe the effect of trastuzumab and cisplatin combined with irinotecan in the treatment of advanced Her-2 positive gastric cancer and its influence on disease control rate.
From January 2018 to January 2021, 120 patients with advanced Her-2 positive gastric cancer admitted to our hospital were selected as the research subjects. According to the treatment plan of the patients, they were divided into a control group and a joint group, with 60 cases in each group; the control group was given trastuzumab + cisplatin, the joint group was treated with irinotecan on this basis, and the clinical effects and disease control rate of the two groups were observed.
After treatment, there were 4 patients with CR in the joint group and 0 patients with CR in the control group. The ORR and DCR of the joint group were significantly higher than those of the control group ( < 0.05). The expression levels of CA199, CEA, and CA724 after treatment in the two groups were significantly reduced ( < 0.05), and the reduction in the joint group after treatment was more evident as compared with the control group ( < 0.05). The joint group witnessed better memory function, physical function, behavioral function, emotional function, and communication function than the control group ( < 0.05), and the scores of all dimensions of the two groups of patients after treatment were superior to those before treatment ( < 0.05). The occurrence of side effects was not statistically different between the two groups of patients ( > 0.05). The 1-year survival rate of the control group was 41.67%, the PFS was 6.33 ± 1.02 months, and the OS was 15.51 ± 2.16 months; the 1-year survival rate of the joint group was 43.33%, and the PFS was 8.05 ± 1.07 months, and OS was 16.03 ± 2.44 months; there was no significant difference in the 1-year survival rate between the two groups ( > 0.05), the difference in PFS between the groups was significant ( = 9.013, < 0.001), and the difference in OS between the groups was not significant ( = 1.236, =0.219).
Trastuzumab + cisplatin combined with irinotecan yields a promising result in the treatment of advanced gastric cancer. It can effectively regulate the expression level of tumor markers, delay disease progression, and improve the quality of life of patients. Moreover, irinotecan will not bring more toxic side effects.
观察曲妥珠单抗联合顺铂与伊立替康治疗晚期Her-2阳性胃癌的疗效及其对疾病控制率的影响。
选取2018年1月至2021年1月我院收治的120例晚期Her-2阳性胃癌患者作为研究对象。根据患者的治疗方案，将其分为对照组和联合组，每组60例；对照组给予曲妥珠单抗+顺铂，联合组在此基础上加用伊立替康，观察两组的临床疗效和疾病控制率。
治疗后，联合组有4例患者达到完全缓解（CR），对照组无CR患者。联合组的客观缓解率（ORR）和疾病控制率（DCR）均显著高于对照组（P<0.05）。两组治疗后糖类抗原199（CA199）、癌胚抗原（CEA）和糖类抗原724（CA724）的表达水平均显著降低（P<0.05），且联合组治疗后的降低程度比对照组更明显（P<0.05）。联合组的记忆功能、身体功能、行为功能、情感功能和沟通功能均优于对照组（P<0.05），两组患者治疗后的各维度评分均优于治疗前（P<0.05）。两组患者副作用的发生情况无统计学差异（P>0.05）。对照组的1年生存率为41.67%，无进展生存期（PFS）为6.33±1.02个月，总生存期（OS）为15.51±2.16个月；联合组的1年生存率为43.33%，PFS为8.05±1.07个月，OS为16.03±2.44个月；两组的1年生存率无显著差异（P>0.05），组间PFS差异有统计学意义（F=9.013，P<0.001），组间OS差异无统计学意义（F=1.236，P=0.219）。
曲妥珠单抗+顺铂联合伊立替康治疗晚期胃癌疗效显著。它能有效调节肿瘤标志物的表达水平，延缓疾病进展，提高患者的生活质量。此外，伊立替康不会带来更多的毒副作用。
